Market ScenarioTMJ disorders is commonly known as temporomandibular joint and muscle disorders. This is a medical condition which causes dysfunction and pain in the jaw joint and the muscles that control jaw movement. This medical condition is more common is women than men. According to the American Academy of Orofacial Pain, TMJ disorders may have more than one symptoms and causes. Some of the major symptoms of this disorder are aching facial pain, tenderness or pain in jaws, pain while chewing etc. TMJ disorders can occur if the joint's cartilage is damaged by arthritis or by a blow or other impact or the disk erodes or moves out of its proper alignment.
Effective diagnosis can provide better treatment management of this disorder. Major diagnostic solution provider companies are engaged in developing and launching new medical imaging devices. Introduction and rapid adoption of advanced diagnostic devices are driving the market growth. Easy availability of medicines is another key driver for the market. Increasing demand for advanced diagnostic devices and treatment, especially from Asia and Latin America is driving the market growth.
The global TMJ disorders market is expected to grow at the CAGR of ~3.9% during the forecast period and is estimated to reach USD 1229.1 million by 2023.
Key Players in the Global TMJ disorders Market
Some of the key players in this market: AbbVie Inc. (US), Allergan (Republic of Ireland), Bayer AG (Germany), Bristol-Myers Squibb Company (US), Jubilant Cadista (US), Pfizer Inc. (US), Sun Pharmaceutical Industries Ltd. (India), and others.
Segments
The global TMJ disorders market is segmented on the basis of diagnosis, which includes physical exam, imaging tests, and others. Imaging tests plays important role in diagnosis of this disorder, these tests may include Computerized Tomography (CT) scan, X-rays, Magnetic Resonance Imaging (MRI), TMJ arthroscopy, and others.
Some of the key players in this market: AbbVie Inc. (US), Allergan (Republic of Ireland), Bayer AG (Germany), Bristol-Myers Squibb Company (US), Jubilant Cadista (US), Pfizer Inc. (US), Sun Pharmaceutical Industries Ltd. (India), and others.
Segments
The global TMJ disorders market is segmented on the basis of diagnosis, which includes physical exam, imaging tests, and others. Imaging tests plays important role in diagnosis of this disorder, these tests may include Computerized Tomography (CT) scan, X-rays, Magnetic Resonance Imaging (MRI), TMJ arthroscopy, and others.
On the basis of treatments, the market is segmented into medications, therapies, surgical or other procedures, alternative medicine, and others. Medications is sub-segmented into pain relievers, anti-inflammatories, tricyclic antidepressants, muscle relaxants, and others. Some therapies also help to cure this disorder such as Oral splints or mouth guards (occlusal appliances), physical therapy, counseling, and others. Some surgical or other procedures includes arthrocentesis, injections, TMJ arthroscopy, modified condylotomy, open-joint surgery, and others. Alternative medicine is also used for the treatment of this disorder such as acupuncture, relaxation techniques, biofeedback, and others.
On the basis of end user, it is segmented into hospitals & clinics, ambulatory surgery centers, academic institutes, medical research centers, and others.
Browse More Report Details @ https://www.marketresearchfuture.com/reports/tmj-disorders-market-4090 NOTE : Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.
No comments:
Post a Comment